These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30902567)

  • 1. Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype.
    Kamiya C; Inui N; Hakamata A; Miyakawa S; Tanaka S; Uchida S; Namiki N; Odagiri K; Watanabe H
    J Pharmacol Sci; 2019 Apr; 139(4):361-366. PubMed ID: 30902567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population.
    Payan M; Rouini MR; Tajik N; Ghahremani MH; Tahvilian R
    Daru; 2014 Dec; 22(1):81. PubMed ID: 25498969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
    Nazir S; Iqbal Z; Ahmad L; Ahmad S
    Pak J Pharm Sci; 2016 May; 29(3):887-94. PubMed ID: 27166533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
    Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
    Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No influence of the CYP2C19-selective inhibitor omeprazole on the pharmacokinetics of the dopamine receptor agonist rotigotine.
    Elshoff JP; Cawello W; Andreas JO; Braun M
    Clin Pharmacol Drug Dev; 2014 May; 3(3):187-93. PubMed ID: 27128608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.
    Román M; Ochoa D; Sánchez-Rojas SD; Talegón M; Prieto-Pérez R; Rivas Â; Abad-Santos F; Cabaleiro T
    Pharmacogenomics; 2014; 15(15):1893-901. PubMed ID: 25495411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19.
    Toda A; Uehara S; Inoue T; Utoh M; Kusama T; Shimizu M; Uno Y; Mogi M; Sasaki E; Yamazaki H
    Xenobiotica; 2018 Jul; 48(7):720-726. PubMed ID: 28686070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
    Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
    Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity.
    Mahmoudi M; Foerster KI; Burhenne J; Weiss J; Mikus G; Haefeli WE
    J Clin Pharmacol; 2021 Jun; 61(6):789-798. PubMed ID: 33236774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.
    Sim SC; Risinger C; Dahl ML; Aklillu E; Christensen M; Bertilsson L; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2006 Jan; 79(1):103-13. PubMed ID: 16413245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeled Hepatic/Plasma Exposures of Omeprazole Prescribed Alone in Cytochrome P450 2C19 Poor Metabolizers Are Likely Associated with Hepatic Toxicity Reported in a Japanese Adverse Event Database.
    Adachi K; Ohyama K; Tanaka Y; Murayama N; Shimizu M; Saito Y; Yamazaki H
    Biol Pharm Bull; 2024; 47(5):1028-1032. PubMed ID: 38797695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
    Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
    Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.
    Michaud V; Kreutz Y; Skaar T; Ogburn E; Thong N; Flockhart DA; Desta Z
    Pharmacogenomics J; 2014 Apr; 14(2):151-9. PubMed ID: 23629159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
    J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.
    Elbe A; Foerster KI; Blank A; Rose P; Burhenne J; Haefeli WE; Mikus G
    Eur J Clin Pharmacol; 2022 Jun; 78(6):975-987. PubMed ID: 35238961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.
    Zhao W; Leroux S; Biran V; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2018 May; 84(5):997-1005. PubMed ID: 29377228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical usefulness of limited sampling strategies for estimating AUC of proton pump inhibitors.
    Niioka T
    Yakugaku Zasshi; 2011 Mar; 131(3):407-13. PubMed ID: 21372537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
    Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.